An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: A phase II study

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 515-522

  Wang, Zhonghua ^a   Lu, Jingsong ^a   Leaw, Shiangjiin ^a   Hong, Xiaonan ^a   Wang, Jialei ^a   Shao, Zhimin ^a   Hu, Xichun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Capecitabine; Metastatic breast cancer; Metronomic cyclophosphamide; Oral chemotherapy; Phase II

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INFORMED CONSENT; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; METASTATIC BREAST CANCER; METRONOMIC DRUG ADMINISTRATION; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; UPREGULATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANOREXIA; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84856714423     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1728-3     Document Type: Article

References (45)

1. EA Perez 2009 Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer Breast Cancer Res Treat 114 195 201 18443902 10.1007/s10549-008-0005-6 1:CAS:528:DC%2BD1MXhsFWnu7o%3D
2. SH Giordano AU Buzdar TL Smith, et al. 2004 Is breast cancer survival improving? Cancer 100 44 52 14692023 10.1002/cncr.11859 (Pubitemid 37553538)
3. E Engelsman JC Klijn RD Rubens, et al. 1991 "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808) Eur J Cancer 27 966 970 1832904 10.1016/0277-5379(91)90259-G 1:STN:280:DyaK38%2FgtVyrsQ%3D%3D
4. JL Blum SE Jones AU Buzdar, et al. 1999 Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 485 493 10080589 1:CAS:528:DyaK1MXht1Wmurw%3D (Pubitemid 29075232)
5. JL Blum V Dieras PM Lo Russo, et al. 2001 Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 1759 1768 11745247 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3. 0.CO;2-A 1:CAS:528:DC%2BD3MXosV2qsLw%3D (Pubitemid 32952493)
6. P Reichardt G Von Minckwitz PC Thuss-Patience, et al. 2003 Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 1227 1233 12881384 10.1093/annonc/mdg346 1:STN:280:DC%2BD3szkvVaruw%3D%3D (Pubitemid 37039048)
7. P Fumoleau R Largillier C Clippe, et al. 2004 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 536 542 14962720 10.1016/j.ejca.2003.11.007 1:CAS:528:DC%2BD2cXhtFWjsbc%3D (Pubitemid 38220770)
8. EA Wist HH Sommer B Ostenstad, et al. 2004 Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer Acta Oncol 43 186 189 15163168 10.1080/02841860310023165 (Pubitemid 38478906)
9. ES Thomas HL Gomez RK Li, et al. 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 5210 5217 17968020 10.1200/JCO.2007.12.6557 1:CAS:528: DC%2BD2sXhsVKnsbzO (Pubitemid 350232252)
10. LG Estévez N Batista P Sánchez-Rovira, et al. 2008 A phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes Clin Breast Cancer 8 149 154 18621611 10.3816/CBC.2008.n.015 (Pubitemid 351655929)
11. G Orphanos A Alexopoulos S Malliou, et al. 2010 A phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines J Cancer Res Clin Oncol 136 115 121 19672628 10.1007/s00432-009-0642-0 1:CAS:528:DC%2BD1MXhsVertr3F
12. JH Ahn SB Kim TW Kim, et al. 2004 Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane J Korean Med Sci 19 547 553 15308846 10.3346/jkms.2004.19.4.547 1:CAS:528:DC%2BD2cXot1Okt7w%3D
13. A Jones M O'Brien H Sommer, et al. 2010 Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes Cancer Chemother Pharmacol 65 755 763 19669644 10.1007/s00280-009-1081-y 1:CAS:528:DC%2BC3cXotVGmsQ%3D%3D
14. R Andres JI Mayordomo R Lara, et al. 2005 Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes Clin Breast Cancer 6 158 162 16001994 10.3816/CBC.2005.n.018 1:CAS:528:DC%2BD2MXntlSqu70%3D (Pubitemid 40975612)
15. M Benekli R Yildiz A Uner, et al. 2007 Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes Oncology 72 308 313 18198492 10.1159/000113053 1:CAS:528:DC%2BD1cXhs1yisL4%3D (Pubitemid 351238142)
16. A Malmström J Hansen L Malmberg, et al. 2010 Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: a phase II study Acta Oncol 49 35 41 19839920 10.3109/02841860903268031
17. R Maisano N Caristi M Mare, et al. 2007 Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study Anticancer Res 27 2871 2875 17695463 1:CAS:528:DC%2BD2sXpvFChtLg%3D (Pubitemid 47228013)
18. C Massacesi A La Cesa F Marcucci, et al. 2006 Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer Oncology 70 294 300 17047400 10.1159/000096250 1:CAS:528:DC%2BD28XhtFGjs7vM (Pubitemid 44670171)
19. B Oksuzoglu H Abali M Hayran, et al. 2008 Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes Chemotherapy 54 352 356 18728366 10.1159/000151630 1:CAS:528:DC%2BD1cXhtFKhtrnM
20. M Donadio M Ardine A Berruti, et al. 2005 Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes Oncology 69 408 413 16319512 10.1159/000089995 1:CAS:528:DC%2BD2MXhtlWiurnM (Pubitemid 41797917)
21. A Polyzos H Gogas C Markopoulos, et al. 2009 Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes Anticancer Res 29 2851 2856 19596973 1:CAS:528:DC%2BD1MXpslyju78%3D
22. P Schmid D Kühnhardt P Kiewe, et al. 2008 A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines Ann Oncol 19 871 876 18209010 10.1093/annonc/mdm569 1:STN:280:DC%2BD1c3nvFWgtw%3D%3D (Pubitemid 351627300)
23. G Schaller I Fuchs T Gonsch, et al. 2007 Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes J Clin Oncol 25 3246 3250 17577021 10.1200/JCO.2006.09.6826 1:CAS:528:DC%2BD2sXhtVWqs7vI (Pubitemid 47325608)
24. T Ishida T Kiba M Takeda, et al. 2009 Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes Cancer Chemother Pharmacol 64 361 369 19082596 10.1007/s00280-008-0882-8 1:CAS:528:DC%2BD1MXms1agu78%3D
25. A Bottini D Generali MP Brizzi, et al. 2006 Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients J Clin Oncol 24 3623 3628 16877730 10.1200/JCO.2005.04.5773 1:CAS:528:DC%2BD28XovVSjsLk%3D (Pubitemid 46630536)
26. M Colleoni L Orlando G Sanna, et al. 2006 Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects Ann Oncol 17 232 238 16322118 10.1093/annonc/mdj066 1:STN:280:DC%2BD28%2FjvVGksQ%3D%3D (Pubitemid 43160111)
27. D Loven E Be'ery R Yerushalmi, et al. 2008 Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients Acta Oncol 47 104 109 17851858 10.1080/02841860701472470 1:CAS:528:DC%2BD2sXhsVCgs7zL
28. N Sawada T Ishikawa Y Fukase, et al. 1998 Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013 1019 9563897 1:CAS:528:DyaK1cXisFeksr4%3D (Pubitemid 28183404)
29. M Endo N Shinbori Y Fukase, et al. 1999 Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models Int J Cancer 83 127 134 10449619 10.1002/(SICI)1097-0215(19990924)83:1<127::AID- IJC22>3.0.CO;2-6 1:CAS:528:DyaK1MXlvF2nt70%3D (Pubitemid 29409488)
30. J O'Shaughnessy D Miles S Vukelja, et al. 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823 12065558 10.1200/JCO.2002.09.002 (Pubitemid 34651510)
31. Lueck H, Minckwitz GV, Bois AD et al. (2006) Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 24:18 s
32. S Ohno S Mitsuyama K Tamura, et al. 2007 Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer Anticancer Res 27 1009 1013 17465235 1:CAS:528:DC%2BD2sXltVKmtbg%3D (Pubitemid 46587014)
33. BT Hennessy AM Gauthier LB Michaud, et al. 2005 Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer Ann Oncol 16 1289 1296 15890665 10.1093/annonc/mdi253 1:STN:280:DC%2BD2MzotFamug%3D%3D (Pubitemid 41158473)
34. G Liu E Franssen MI Fitch, et al. 1997 Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 110 115 8996131 1:STN:280:DyaK2s7kvFehsQ%3D%3D (Pubitemid 27021524)
35. CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 17192538 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D (Pubitemid 46021510)
36. KD Miller LI Chap FA Holmes, et al. 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799 15681523 10.1200/JCO.2005.05.098 1:CAS:528:DC%2BD2MXitVKitrk%3D (Pubitemid 46224178)
37. G von Minckwitz A du Bois M Schmidt, et al. 2009 Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 1999 2006 10.1200/JCO.2008.19.6618
38. NJ Robert V Dieras J Glaspy, et al. 2011 RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 1252 1260 21383283 10.1200/JCO.2010.28.0982 1:CAS:528:DC%2BC3MXntlKlsb8%3D
39. A Brufsky IN Bondarenko V Smirnov, et al. 2009 RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trialevaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer Cancer Res 69 24 Supplement 42 10.1158/0008-5472.SABCS-09-42
40. M Tanaka Y Takamatsu K Anan, et al. 2010 Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study Anticancer Drugs 21 453 458 20075712 10.1097/CAD.0b013e328336acb1 1:CAS:528:DC%2BC3cXivV2rsLk%3D
41. DK Tong CW Cheng S Ching Chan, et al. 2005 Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer-safety, efficacy and quality of life Oncology 68 520 525 16037685 10.1159/000086996 1:CAS:528:DC%2BD2MXnvFymtr4%3D (Pubitemid 41160985)
42. AF Schott D Lew WE Barlow, et al. 2010 Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC) J Clin Oncol 28 15s
43. DG Haller J Cassidy S Clarke, et al. 2006 Tolerability of fluoropyrimidines appears to differ by region J Clin Oncol 24 18s 10.1200/JCO.2006.06.1143
44. G Bonadonna E Brusamolino P Valagussa, et al. 1976 Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 405 410 1246307 10.1056/NEJM197602192940801 1:STN:280:DyaE287gtVKrtA%3D%3D
45. MN Levine VH Bramwell KI Pritchard, et al. 1998 Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 16 2651 2658 9704715 1:CAS:528:DyaK1cXlsFCguro%3D (Pubitemid 28363028)